Kairos Pharma, Ltd.
KAPA
$0.96
$0.05265.80%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -207.98% | -147.04% | -106.97% | -72.57% | -- |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Total Amortization of Deferred Charges | 350.00% | -37.50% | -81.67% | -86.27% | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -283.81% | 163.58% | 327.63% | 492.25% | -- |
| Cash from Operations | -3,762.96% | 112.69% | 158.69% | 122.95% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -54.67% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -24.86% | -87.78% | -84.17% | -152.98% | -- |
| Cash from Financing | 1,506.49% | -624.44% | -209.14% | -159.27% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 835.38% | -38.82% | -265.10% | -194.51% | -- |